Table 2.
Impact of Bevacizumab in addition to Carboplatin and Paclitaxel on Hazard Ratios for Overall Survival
| Model | Sample Size
|
Hazard Ratio (95% CI)
|
||
|---|---|---|---|---|
| BCP, CP 2006–7 | BCP, CP 2002–5 | BCP vs. CP 2006–7 | BCP vs. CP 2002–5 | |
| Unadjusted model | 318, 1,182 | 318, 2,664 | 1.00 (0.88–1.14) | 0.95 (0.84–1.08) |
|
| ||||
| Multivariable adjusted model a | 318, 1,182 | 318, 2,664 | 1.01 (0.88–1.15) | 0.94 (0.83–1.06) |
|
| ||||
| Propensity score-adjusted model b | ||||
|
| ||||
| Stratification | 318, 1,153 | 311, 2,512 | 1.01 (0.89–1.16) | 0.93 (0.83–1.06) |
|
| ||||
| Within propensity score quintile | ||||
|
| ||||
| 1 (lowest propensity) | 33, 261 | 51, 716 | 0.75 (0.51–1.10) | 0.97 (0.72–1.30) |
|
| ||||
| 2 | 69, 337 | 84, 795 | 1.06 (0.80–1.39) | 0.92 (0.73–1.17) |
|
| ||||
| 3 | 110, 361 | 107, 640 | 1.06 (0.85–1.32) | 0.97 (0.79–1.20) |
|
| ||||
| 4 | 78, 151 | 52, 299 | 1.16 (0.87–1.55) | 0.81 (0.59–1.11) |
|
| ||||
| 5 (highest propensity) | 28, 43 | 17, 62 | 0.84 (0.48–1.47) | 1.07 (0.61–1.91) |
|
| ||||
| Regression adjustment | 318, 1,153 | 311, 2,512 | 1.01 (0.89–1.16) | 0.94 (0.83–1.06) |
|
| ||||
| Weighting (stabilized IPTW) | 318, 1,153 | 311, 2,512 | 0.99 (0.87–1.13) | 0.93 (0.82–1.06) |
|
| ||||
| Matching 1:1 | 318, 318 | 318, 318 | 0.99 (0.79–1.23) | 0.90 (0.72–1.13) |
|
| ||||
| Subgroup analyses | ||||
|
| ||||
|
| ||||
| Stage IV c | 262, 838 | 262, 1,848 | 0.96 (0.83–1.12) | 0.88 (0.77–1.02) |
|
| ||||
| Estimated comorbidity score of 0 d | 210, 665 | 210, 1,661 | 1.04 (0.87–1.23) | 0.92 (0.79–1.08) |
|
| ||||
| Sensitivity analyses a | ||||
|
| ||||
| Patients surviving >8 days from treatment start | 315, 1,173 | 315, 2,637 | 1.00 (0.87–1.15) | 0.91 (0.80–1.03) |
|
| ||||
| Patients first treated with bevacizumab between 1 and 30 days of starting CP and surviving >30 days from treatment start | 342, 1,068 | 342, 2,478 | 0.98 (0.86–1.12) | 0.89 (0.79–1.01) |
Abbreviations: CI, confidence interval; BCP, bevacizumab-carboplatin-paclitaxel; CP 2006–7, carboplatin-paclitaxel (diagnoses 2006–7 when bevacizumab was FDA approved for NSCLC); CP 2002–5, carboplatin-paclitaxel (diagnoses 2002–5 when bevacizumab was not available (2002–3) or not approved for NSCLC treatment); IPTW, inverse probability of treatment weighting.
The model was adjusted for baseline age, sex, race/ethnicity, marital status, geographic region, urban residency, tumor grading, census tract education, median income, modified Charlson comorbidities, and AJCC stage.
The propensity of receiving BCP was estimated using multivariable logistic regression model that included baseline age, sex, race/ethnicity, marital status, geographic region, urban residency, tumor grading, census tract education, median income, modified Charlson comorbidities, and AJCC stage.
The model was adjusted for baseline age, sex, race/ethnicity, marital status, geographic region, urban residency, tumor grading, census tract education, median income, and modified Charlson comorbidities.
The model was adjusted for baseline age, sex, race/ethnicity, marital status, geographic region, urban residency, tumor grading, census tract education, median income, and AJCC stage.